No Detail Found!

Hyperammonemia in patients on valproic acid therapy in a tertiary care hospital of Karachi

Author(s)
Iqra Ali Clinical Data Specialist, Dr. A. Q. Khan Institute of Behavioral Sciences, Karachi, Pakistan
Bashir Ahmed Soomro Department of Neurology, Ziauddin Hospital, Karachi, Pakistan
Farrukh Malik Department Cardiology, National Institute of Cardiovascular Diseases, Karachi, Pakistan
Abstract
OBJECTIVE: To assess the incidence of hyperammonemia in patients receiving valproic acid (VPA) therapy. METHODS: This cross-sectional study was conducted at the Department of Neurology, Ziauddin Medical University and Hospital, Karachi, for six months from April to October 2019. A total of 158 patients of both genders, aged between 18 to 80 years, presented in emergency with complaints of seizures and who had received a minimum dose of valproic acid before blood withdrawal were included. Pregnant women, patients with cirrhotic liver, or chronic renal impairment were excluded from the study. RESULTS: Out of 158 patients, 80 (50.6%) were females and 78 (49.4%) were males. Mean age of patients was 55.53±18.26 years. Among the participants, 27 (17.1%) had undergone VPA therapy for 30 days or more, while 131 (82.9%) had received it for less than 30 days. The mean duration of VPA therapy was 8.58±10.41 days. Among the 158 patients, 95 (60.1%) with seizures receiving VPA treatment were diagnosed with hyperammonemia. The mean serum ammonia level was 66.50±44.59 mg/dL, and mean VPA dose administered was 1000±125 mg/day. There was a statistically significant association between the dose of VPA and the incidence of hyperammonemia (p <0.05). Patients receiving a daily dose of VPA exceeding 1000 mg were more likely to develop hyperammonemia. CONCLUSION: This study revealed a high incidence of hyperammonemia among patients undergoing VPA therapy, with 60.1% of the total patients receiving VPA therapy experiencing hyperammonemia.
Publication Details
Page(s) 183-186
Published Journal: Khyber Medical University Journal, Volume: 15, Issue: 3, Year: 2023

Request the full text from PASTIC

Keywords
Seizures (MeSH), Valproic Acid (MeSH), Hyperammonemia (MeSH), Valproic acid therapy (Non-MeSH)
0

Citations

0

Downloads

31

Views